Kala Pharmaceuticals announced the closing of its initial public offering of 6,900,000 shares of common stock, including the underwriters’ exercise in full of their option to purchase an additional 900,000 shares, at the public offering price of $15 per share. The exercise of the underwriters’ option brought the amount of gross proceeds raised in the offering to approximately $103.5 million, before underwriting discounts, commissions and estimated expenses of the offering.
J.P. Morgan, BofA Merrill Lynch and Wells Fargo Securities acted as joint bookrunners for the offering. Wedbush PacGrow acted as a co-manager for the offering.
A registration statement relating to the shares of common stock being sold in this offering has been filed with the U.S. Securities and Exchange Commission and was declared effective on July 19, 2017.